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Abstract: Inhibitors of cyclo-oxogenase (COX) are widely used anti-inﬂ  ammatory drugs. 
In recent years concerns have arisen about the cardiovascular safety of these drugs, initially 
because of reported associations between therapy with the COX-2 selective inhibitor rofecoxib 
and myocardial infarction. However, subsequent data have suggested an association between 
therapy with non-selective COX inhibitors (NSAIDs) and serious cardiovascular events. This 
article reviews the clinical trial and population data linking COX inhibition to cardiovascular 
events. The data currently available suggests that both speciﬁ  c and non-speciﬁ  c COX inhibi-
tors may increase the risk of serious cardiovascular events, but that the effect varies between 
the individual drugs. The strongest evidence for an increased risk of serious cardiovascular 
events is with rofecoxib therapy. Celecoxib therapy may be associated with an increased risk 
of cardiovascular events, but only when used at doses substantially higher than those recom-
mended for the treatment of arthritis. There is a greater body of evidence supporting the relative 
cardiovascular safety of celecoxib when used at the doses recommended for the treatment of 
arthritis than for any of the other selective COX-2 inhibitors or NSAIDs.
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Introduction
During the last few years there has been considerable concern about the adverse 
cardiovascular effects of selective cyclo-oxygenase-2 (COX-2) inhibitors. This arose 
initially because of reports of adverse effects of rofecoxib, but the concern spread to 
include other selective COX-2 inhibitors as it was thought that the problem may have 
been a class effect related to a potential pro-thrombotic state induced by unopposed 
COX-2 inhibition. However, closer scrutiny of the relationship between therapy with 
traditional non-selective COX inhibitors (NSAIDs) and cardiovascular events has 
suggested that an increased risk of cardiovascular events may occur with a number of 
members of the class and that this risk may not be related to degree of COX selectivity. 
This paper reviews the information available from clinical trials and population studies 
concerning the relationship between selective COX-2 inhibitor or NSAID therapy and 
cardiovascular events, and focuses on the question of whether or not celecoxib – the 
most widely prescribed remaining member of the selective COX-2 inhibitors has the 
greatest evidence for cardiovascular safety.
Methods
A comprehensive database search was performed on Medline and PubMed using the 
search terms COX-2, celecoxib, rofecoxib, lumiracoxib, etoricoxib, non-steroidal 
anti-inﬂ  ammatory and myocardial infarction, stroke or cardiovascular events from 
1965 to August 2006. The search was limited to human studies. References from 
each publication were checked for additional publications. All randomized, controlled Therapeutics and Clinical Risk Management 2007:3(5) 832
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studies and population studies were included. Beyond this, 
no attempt to judge the quality of the individual studies was 
made as it was felt that this may introduce an unwarranted 
potential for subjectivity. In addition, the US FDA website 
was accessed to obtain reports concerning the cardiovascular 
adverse event assessments of rofecoxib, etoricoxib and 
celecoxib.
A separate search of Medline was performed for both 
clinical and pre-clinical studies which have investigated 
possible mechanisms for an increase in cardiovascular events 
with these drugs, as well as for reviews on the topic.
Long-term placebo controlled trials
There has been one long term placebo controlled trial 
involving rofecoxib, studying the prevention of intestinal 
polyps (Bresalier et al 2005), three involving celecoxib 
(Arber et al 2005; Solomon et al 2005; TMT review 2005), 
and one involving naproxen (TMT review 2005). Two of 
the celecoxib studies were on the prevention of intestinal 
polyps (APC and pre-SAP) and one placebo controlled study 
of both celecoxib and naproxen examined the prevention of 
Alzheimers disease progression (ADAPT). An assessment 
of cardiovascular endpoints in these trials was made from 
the reporting of adverse events. With the exception of the 
ADAPT trial, there are no long term placebo controlled 
studies from which the cardiovascular safety of NSAIDS can 
be assessed. It is therefore possible that any adverse ﬁ  ndings 
detected in any of the long term placebo controlled trials with 
celecoxib or rofecoxib may also occur with NSAIDS.
The APPROVe study
The APPROVe study was a 3-year, placebo-controlled study 
of rofecoxib 25 mg daily in the prevention of adenomatous 
colonic polyps (Bresalier et al 2005). The study enrolled 2586 
patients with a history of colorectal adenoma, 1287 of whom 
received rofecoxib 25 mg daily and 1299 of whom received 
placebo. Patients with a history of ischemic heart disease 
or cerebrovascular disease were excluded. Monitoring of 
cardiovascular events was a planned component of the 
trial. Potential cardiovascular endpoints were adjudicated 
in a blinded manner. Serious adverse cardiovascular events 
were deﬁ  ned as fatal and non-fatal myocardial infarction, 
unstable angina, sudden death from cardiac causes, fatal 
and non-fatal ischemic stroke, transient ischemic attack, 
peripheral arterial thrombosis, peripheral venous thrombosis, 
and pulmonary embolism. The patients were followed for 
approximately three years (3059 patient-years). After about 
18 months of therapy a statistically signiﬁ  cant difference 
in cardiovascular events was found between the patients 
receiving rofecoxib and those receiving placebo (Figure 1). 
Forty ﬁ  ve patients receiving rofecoxib experienced a serious 
cardiovascular thromboembolic event compared to 25 
of the patients receiving placebo (relative risk 1.92, 95% 
confidence intervals 1.19 to 3.11, P = 0.008). Major 
contributors to the excess number of cardiovascular events 
in patients receiving rofecoxib were myocardial infarction 
(21 on rofecoxib verses 9 on placebo) and ischemic stroke 
(11 verses 6). These ﬁ  ndings led the manufacturer Merck Pty 
Ltd to voluntarily withdraw the drug from marketing at the 
beginning of October 2004. A signiﬁ  cantly greater number 
of patients developed hypertension on rofecoxib therapy 
than on placebo (14.3% verses 7.3%), a factor which could 
have contributed to the higher incidence of cardiovascular 
events on rofecoxib therapy.
The APC and pre-SAP studies
The APC and pre-SAP studies were both double blind, 
randomized, placebo controlled trials studying the use of 
celecoxib for the prevention of new adenomatous colonic 
polyps. The APC study was a three-arm study comparing 
celecoxib 200 mg bd, 400 mg bd and placebo. The pre-SAP 
study was a two-arm study comparing celecoxib 400 mg once 
daily with placebo. It was planned to follow up patients in 
each study after one and three years. The APC study enrolled 
a total of 2035 patients who were equally divided into the 3 
groups. The pre-SAP study enrolled 1561 patients, ∼900 in 
the celecoxib arm and ∼600 in the placebo arm (Arber et al 
2005; Bertagnolli et al 2006; Solomon et al 2005; TMT 
review 2005).
After the withdrawal from marketing of rofecoxib, an 
independent panel of cardiovascular experts was formed 
who adjudicated all reported serious adverse events for cele-
coxib from the APC and pre-SAP trials in a blinded manner. 
Adverse events that were considered to be of a cardiovascular 
nature were selected for analysis and further categorized into 
groups reﬂ  ecting the probable type of cardiovascular event 
which had occurred. The data were subsequently unblinded 
and analysed. The principle group of endpoints that were of 
primary interest was the combination of cardiovascular death 
(or resuscitated cardiac arrest), fatal or non-fatal myocardial 
infarction, and fatal or non fatal stroke (CV death/MI/stroke), 
as these had been the events which had been found to be 
elevated during rofecoxib therapy compared to placebo in 
the APPROVe study.
The incidence of cardiovascular (CV) death/MI/stroke in 
APC was 0.8% for placebo, 2.1% for celecoxib 200 mg bd Therapeutics and Clinical Risk Management 2007:3(5) 833
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Figure 1 Cumulative incidence of cardiovascular events on rofecoxib and placebo therapy in the APPROVe Study.
and 2.8% for celecoxib 400 mg bd. In pre-SAP the incidences 
were originally reported to be 1.9% for placebo and 2.2% for 
celecoxib 400 mg daily (TMT review, 2005) but a subsequent 
report of the results by the investigators altered this slightly to 
1.9% and 2.2% respectively (Arber et al 2005). It is unclear 
whether the slightly higher number of events represented 
more reported cases of CV death/MI/stroke or the inclusion 
of heart failure as an endpoint (Arber et al 2005). In the 
APC study, the difference between celecoxib 200 mg bd and 
placebo was of marginal statistical signiﬁ  cance (odds ratio 
2.8, 95% conﬁ  dence interval 1.0 to 7.7) while the difference 
between celecoxib 400 mg bd and placebo was statistically 
signiﬁ  cant (odds ratio 3.2, 95% conﬁ  dence intervals 1.2 to 
8.8; P = 0.01). It was the ﬁ  ndings of the APC study that 
raised safety concerns within regulatory bodies. However, in 
the pre-SAP study the incidence of CV death/MI/stroke was 
similar for placebo and celecoxib 400 mg once daily irrespec-
tive of whether or not heart failure was included (hazard ratio 
1.2, 95% conﬁ  dence interval 0.6 to 2.5) (Arber et al 2005). 
This result was difﬁ  cult to reconcile with the results of the 
APC study considering the similar study design.
The incidence of the CV death/MI/stroke endpoint was 
similar for celecoxib at a total daily dose 400 mg in each study 
(2.1% and 2.2%). The incidence of this endpoint for placebo 
in the pre-SAP study (1.9%) was similar to that of the 400 mg 
doses in both studies but the incidence of the endpoint 
appeared lower for placebo in the APC study (0.8%). Thus 
the incidence of CV death/MI/stroke for placebo in the APC 
study may have been spuriously low, particularly considering 
the small number of endpoints that the conclusions from the 
APC study have been drawn from.
A further issue is the use of myocardial infarction as 
an endpoint in clinical trials without other indicators of 
myocardial ischemia. This has been debated frequently in 
recent times due to the changing classiﬁ  cation, diagnosis and 
management of ischemic heart disease. The distinction be-
tween a diagnosis of myocardial infarction and admission to 
hospital with unstable angina (acute coronary syndrome) has 
become less clear. Most importantly, early interventions with 
procedures such as angioplasty have undoubtedly prevented 
many myocardial infarctions. When evaluating myocardial 
ischemic events it is therefore more relevant to use a com-
bination of myocardial infarction, hospital admission for 
unstable angina and unplanned coronary revascularization. 
This was done in the evaluation of the APPROVe study but 
not in the published cardiovascular events of the APC and 
pre-SAP studies.
The data from the APC and pre-SAP studies using 
a combined endpoint of CV (sudden) death, stroke, 
myocardial infarction, hospitalization for unstable angina 
and cardiovascular procedures are presented in Table 1. It 
should be noted that these data are complete only up until 
about February 2005 and the ﬁ  nal publication of the APC 
and pre-SAP studies included a small number of events 
that were reported subsequent to this date (Bertagnolli et 
al 2006) (complete data including unstable angina have not 
been reported).
It can be seen from the result of this analysis of all 
ischemic cardiac events and stroke that there is relative 
consistency in the percentage of events occurring on 
celecoxib therapy and on placebo therapy between the APC 
and pre-SAP studies; there are no statistically signiﬁ  cant Therapeutics and Clinical Risk Management 2007:3(5) 834
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differences between celecoxib and placebo and there is no 
evidence of an increase in the number of events at the higher 
dose of 800 mg/day of celecoxib in the APC study.
Nonetheless, the publicized results of the APC and 
pre-SAP studies have raised the suspicion that high doses 
of celecoxib (two to four times the usual dose used for the 
treatment of arthritis) may be associated with an increased 
risk of cardiovascular events, but this is not as convincing 
as for the effects of rofecoxib at a dose routinely used for 
the management of arthritis.
The ADAPT study
The ADAPT study was a long-term, randomized, double 
blinded, placebo controlled investigation of the effects of 
celecoxib 200 mg bd or naproxen 220 mg bd on the devel-
opment of dementia in elderly subjects who had a history of 
dementia in a ﬁ  rst degree relative (TMT review, 2005). The 
intention was to study approximately 2500 patients equally 
divided into the three groups for a period of 7 years. The 
Treatment Effects Monitoring Committee (TEMC) met 
every 6 months and at its 10 December meeting considered 
data available up to the 1 October 2004, which included 
750 patients who had been exposed to celecoxib for greater 
than 1.5 years. They concluded there was no reason to 
cease the trial. However, on 17 of December in response 
to the suspension of celebrex administration in the APC 
and pre-SAP trials, the executive board of the ADAPT 
trial suspended enrolment and study drug administration 
to ADAPT patients. The TEMC for the ADAPT study 
released the principle results of the safety analysis that had 
been prepared for their 10th of December meeting. These 
results indicated signiﬁ  cantly higher risks of gastrointes-
tinal bleeding, cardiovascular and cerebrovascular events 
in patients taking naproxen compared to placebo but no 
increase in these risks for celecoxib compared to placebo. 
The TEMC subsequently supplemented these data with 
safety reports of adverse events that had not previously 
been captured.
All adverse event forms and death reports were reviewed 
by a committee of three physicians involved with the study 
but who were unaware of the associated study drug treatment 
to ensure consistency of the event categorization. The main 
outcome measure was that used by the Anti-Platelet Trialists 
Collaboration, which is CV (sudden death)/MI/stroke. The 
potential limitations of this endpoint have been discussed 
above. A further limitation is that it does not include cerebral 
transient ischemic attacks (TIA’s). However, TIA’s were 
adjudicated and included in the presentation of the data. 
The results of the cardiovascular adverse events reported in 
the ADAPT Study are presented in Table 2. The odds ratios 
with 95% conﬁ  dence limits and P values for comparisons 
between celecoxib or naproxen and placebo corresponding 
to Table 5 are presented in Table 3.
It is of interest that the only result of statistical signiﬁ  -
cance was a higher risk of CV death/AMI/stroke/TIA for 
the non-speciﬁ  c NSAID naproxen compared to placebo. 
This appeared to be largely due to an increased incidence of 
stroke. Naproxen inhibits both COX-1 and COX-2 and does 
not disturb the balance between prostacyclin and thrombox-
ane production.
After at least 1.5 years of therapy with celecoxib 400 mg in 
elderly patients there were no signiﬁ  cant differences between 
celecoxib and placebo for any of the cardiovascular endpoints 
retrospectively assessed from reported adverse events. In con-
trast, the reported incidence for the composite cardiovascular 
endpoint was signiﬁ  cantly higher in the subjects who received 
naproxen compared to those that received placebo.
Conclusions from long-term 
placebo-controlled clinical trials
The placebo controlled trials of selective COX-2 inhibitors 
and the NSAID naproxen suggest an increased risk of serious 
Table 1 Serious cardiovascular events in the APC and pre-SAP 
studies including unstable angina and emergency (unplanned) 
revascularizations
 APC  pre-SAP
  Placebo  200 mg bd  400 mg bd  Placebo  400 mg od
  (n = 679) (n = 685)  (n = 671)  (n = 628) (n = 933)
Number  18  28 27 19  38
of events
Percent  2.6  4.0 4.0 3.0  4.0
Odds  ratio    1.56 1.53   1.36
    (0.85–2.85) (0.83–2.82)   (0.77–2.38)
p  vs    0.14 0.16   0.27
placebo
Table 2 Incidence of serious cardiovascular events in the 
ADAPT study
Event Celecoxib  Naproxen  Placebo
  (n = 704)  (n = 702)  (n = 1057)
Myocardial infarct   10 (1.42%)  9 (1.28%)  10 (0.95%)
Stroke  10 (1.42%)  12 (1.70%)  8 (0.76%)
CV death/AMI/  17 (2.41%)  21 (2.99%)  20 (1.89%)
stroke
CV death/AMI/  22 (3.13%)  30 (4.27%)  25 (2.37%)
stroke/TIATherapeutics and Clinical Risk Management 2007:3(5) 835
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adverse cardiovascular events of about 2-fold in patients 
receiving rofecoxib 25 mg daily. Naproxen therapy may be 
associated with an increased risk of stroke. The studies do 
not provide convincing evidence of an increase in the risk 
of cardiovascular events during celecoxib therapy, although 
is possible that higher doses of celecoxib (800 mg per day) 
may be associated with an increased cardiovascular risk 
based on the results of the APC study. It should be empha-
sized that similar long term, placebo controlled studies have 
not been performed with NSAIDs other than naproxen, so 
it is unknown whether they may be associated with similar 
indications of an increased cardiovascular risk.
Comparative trials between COX-2 
speciﬁ  c inhibitors and NSAIDS
The VIGOR Study (Bombardier et al 2000) was designed to 
compare the gastrointestinal safety of rofecoxib with naproxen 
in patients with rheumatoid arthritis; 8076 patients were 
randomized to receive rofecoxib 50 mg per day or naproxen 
500 mg daily and followed for a mean duration of 9 months. 
The incidence of serious cardiovascular thrombotic events 
was signiﬁ  cantly higher in patients who received rofecoxib 
than in those that received placebo (Figure 2) principally due 
to a higher incidence of myocardial infarction (0.4 percent 
verses 0.1 percent). A subsequent analysis by the US FDA, 
which included additional adverse cardiovascular events to 
those available when the CLASS study was published, pro-
duced similar ﬁ  ndings. The results of this study generated a 
lot of discussion, including the proposal that the results were 
evidence that the imbalance on prostacyclin and thrombox-
ane formation that resulted from COX-2 speciﬁ  c inhibition, 
predisposed patients to adverse cardiovascular events.
Although numerous comparative studies between 
celecoxib and NSAIDS have been performed, most have 
been of short duration. The longest and largest comparative 
study between celecoxib and NSAIDS was the CLASS Study 
(Silverstein et al 2000; White et al 2002). This was a comparison 
of an average of 9 months of therapy with either celecoxib 
or one of the NSAIDS, ibuprofen or diclofenac. The aim of 
the study was to compare the incidence of gastro-intestinal 
ulceration between the therapies. Celecoxib was given at 
a dose of 400 mg twice daily, while the NSAIDS were 
administered at their usual recommended therapeutic doses 
(ibuprofen 800 mg three times a day and diclofenac 75 mg 
twice daily). Approximately 22% of the population studied 
also took low dose aspirin (which also inhibits both COX-1 
and COX-2) as prophylaxis against cardiovascular disease. 
Patients were enrolled into the study if they suffered from 
either rheumatoid arthritis or osteoarthritis; 3987 patients 
were randomized to receive celecoxib and 3981 patients 
received either ibuprofen or diclofenac in approximately 
equal numbers.
Adverse events were classiﬁ  ed retrospectively by the 
investigators (White et al 2002) into three cardiovascular 
groups: cardiac (myocardial infarction, myocardial isch-
emia, unstable angina, cardiac arrest or sudden death, other 
cardiac death); cerebrovascular (stroke, TIA); and peripheral 
vascular events.
There were no signiﬁ  cant differences between any of 
the single or composite outcomes between celecoxib and 
NSAIDS except for stroke (which presumably also included 
TIA). The incidence of stroke was signiﬁ  cantly lower in 
patients receiving celecoxib than in the combined NSAID 
groups. The odds ratio for patients receiving NSAIDS having 
a higher risk of stroke was 2.98 (95% conﬁ  dence intervals 
0.96–9.25; P = 0.047). A selection of the same cardiac 
endpoints that used in the analysis of the placebo controlled 
trials which reﬂ  ect ischemia – CV (sudden) death, stroke, 
myocardial infarction, myocardial ischemia and unstable 
angina (information was not provided concerning coronary 
revascularizations) produced an odds ratio for this group 
of endpoints of 1.19 (95% conﬁ  dence intervals 0.70–2.04; 
P = 0.50).
A separate analysis of the 78% of patients who were 
not taking aspirin was also performed by the investigators. 
Overall the results were similar to those obtained in the 
whole study population. For the combined endpoint of CV 
(sudden) death, stroke, myocardial infarction, myocardial 
ischemia and unstable angina the odds ratio was 0.75 (95% 
conﬁ  dence intervals 0.35–1.59; p = 0.45).
It can be concluded from the CLASS study that over a 
period of approximately 9 months the risk of adverse cardio-
vascular events on celecoxib therapy appears to be similar to 
Table 3 Odds ratios and statistical signiﬁ  cance of differences 
in serious adverse events between naproxen or celecoxib and 
placebo in the ADAPT study
Event   Celecoxib vs  Naproxen vs
 placebo  placebo
Myocardial infarct  1.50 (0.62–3.64)  1.36 (0.55–3.37)
  P = 0.35  p = 0.50
Stroke 1.88  (0.74–4.81)  2.28  (0.92–5.6)
  P = 0.18  p = 0.06
CV death/AMI/stroke  1.28 (0.66–2.46)  1.59 (0.86–2.97)
  P = 0.45  p = 0.13
CV 1.33  (0.74–2.38)  1.84 (1.07–3.61)
death/AMI/Stroke/TIA  P = 0.33  p = 0.02Therapeutics and Clinical Risk Management 2007:3(5) 836
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that which occurs during therapy with two commonly used 
NSAIDS, with the exception of stroke which appeared to be 
more common in patients receiving NSAIDs. As there was 
no placebo group, the study was unable to determine whether 
both groups of drugs have no effect on cardiovascular events 
or they have similar adverse effects. It should be noted that 
the average duration of the CLASS study was 9 months. It 
is possible that longer comparative studies may produce 
different results.
It is of interest to examine the cardiovascular events that 
occurred on celecoxib therapy compared to the individual 
NSAIDS studied, ibuprofen and diclofenac. The rate of accu-
mulation of adverse cardiovascular events during the CLASS 
study for each of the drugs used is presented in Figure 3. In 
the top part of the Figure (A), the celecoxib group and both 
NSAIDS combined data are compared, while in the bottom 
part of the Figure (B) celecoxib and the individual NSAIDS 
are compared.
While there was no difference in the rate of cardiovascular 
events when celecoxib was compared to the combination 
of the two NSAIDS, the lower part of the Figure gives the 
impression that there may have been differences between the 
rates of cardiovascular events between the two NSAIDS, with 
diclofenac having a higher rate than ibuprofen and celecoxib 
lying somewhere in the middle. While these differences were 
not statistically signiﬁ  cant, they are of interest considering 
the epidemiology data suggesting differences in the risk of 
myocardial infarction between NSAIDS which is discussed 
below. Some of these data suggest that ibuprofen may have a 
relatively lower risk of thromboembolic events while diclof-
enac may have a relatively higher risk (Johnsen et al 2005; 
Hippisley-Cox et al 2005; Andersohn et al 2006).
A pooled analysis of cardiovascular adverse events 
from 15 studies that compared celecoxib with NSAIDS or 
placebo was published by White et al in 2003 (White et al 
2003). (This analysis did not include the APC study or the 
pre-SAP study which were completed after this time). With 
the exception of the CLASS study, most of the studies were 
either of short duration or involved relatively small numbers 
of patients. The CLASS study therefore contributed most of 
the data to the pooled analysis and the results not surpris-
ingly were similar to those reported for the CLASS Study. 
Adverse events were adjudicated in a blinded manner by the 
investigators and the endpoint used for comparison between 
therapies was a combination of myocardial infarction, myo-
cardial ischemia, unstable angina, cardiac revascularizations, 
death (including cardiac and sudden or unexplained deaths), 
stroke and TIA.
Figure 2 Cumulative incidence of serious cardiovascular events on rofecoxib and naproxen in the VIGOR study.
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No signiﬁ  cant differences in serious cardiovascular events 
were found between celecoxib and NSAIDS (including naproxen 
alone) or between celecoxib and placebo. The relative risk for 
the combined endpoint was 0.85 (95% conﬁ  dence intervals 
0.23–3.15, p = 0.81) for the comparison between celecoxib and 
placebo and 1.06 (95% conﬁ  dence intervals 0.70 –1.61, P = 0.79). 
However the limited extent of exposure in the studies comparing 
celecoxib with placebo should be noted. Hence this study was 
principally one comparing celecoxib with other NSAIDS.
A meta-analysis was provided by Pfizer Pty Ltd in 
response to requests by the European Medicines Evaluation 
Agency (EMEA) which included 41 randomized, controlled 
clinical trials involving 44,308 patients studied for between 
2 weeks and 12 months (Pﬁ  zer- data on ﬁ  le, 2005). The APC, 
pre-SAP and ADAPT trials were not included in this analysis. 
The data included 1268 patient-years of exposure to cele-
coxib in trials compared with 585 patient years of exposure 
to placebo. The relative risk for any serious cardiovascular 
thromboembolic event was 1.02 (95% conﬁ  dence intervals 
0.49–2.13; P = 0.957).The relative risk for the same endpoint 
compared to all NSAIDs (5651 patient-years of exposure for 
celecoxib and 4386 patient years of exposure for NSAIDs) 
Figure 3 Cumulative incidence of serious cardiovascular events on celecoxib compared to the combined NSAID group (Upper Panel A) and compared to the individual 
results for ibuprofen and diclofenac (Lower Panel B).Therapeutics and Clinical Risk Management 2007:3(5) 838
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was 0.88 (0.65–1.19; P = 0.403). No signiﬁ  cant differences 
in the results were observed between aspirin users and 
non-aspirin users. However, of interest was a statistically 
signiﬁ  cantly lower incidence of stroke in celecoxib users 
compared to NSAID users. These results are in keeping 
with those of the CLASS and ADAPT studies, which found 
a lower incidence of stroke in celecoxib users than in the 
patients receiving NSAIDs.
It has been suggested the apparent adverse cardiovascular 
effects of rofecoxib in the VIGOR study may have been due 
to the fact that rofecoxib was a more speciﬁ  c inhibitor of 
COX-2 than celecoxib. This proposition may be supported 
by the ﬁ  ndings of pooled analysis of randomized controlled 
trials of etoricoxib, another highly selective COX-2 inhibitor, 
which suggest an increased risk of cardiac ischemic events 
for etoricoxib compared to either placebo or NSAIDs – 
although the number of events that this analysis is based on 
is relatively small (Food and Drug Administration 2005). 
However, a subsequent 12-month study comparing another 
COX-2 speciﬁ  c inhibitor, lumiracoxib – which is more 
COX-2 selective than rofecoxib (Farouk et al 2004) – with 
two NSAIDS (naproxen or ibuprofen) found no signiﬁ  cant 
differences in cardiovascular events between the groups. 
This study had over 9000 patients with osteoarthritis in 
each of the lumiracoxib and combined NSAID arms, and 
cardiovascular events (myocardial infarction, unstable 
angina, cardiovascular death, cardiac arrest, stroke (ischemic 
and haemorrhagic), transient ischemic attack, deep vein 
thrombosis, and pulmonary embolism) were pre-speciﬁ  ed 
study endpoints. The hazard ratio for cardiovascular events 
between the lumiracoxib and NSAID arm was 1.14 (95% 
conﬁ  dence intervals 0.78–1.66; P = 0.50). Similar results 
were obtained in patients receiving low dose aspirin as 
cardiovascular prophylaxis and those not receiving low dose 
aspirin. The study has been criticized because the number of 
cardiovascular events was low and patients with a signiﬁ  cant 
risk of cardiovascular events were excluded. However, the 
number of myocardial infarctions (21 in the lumiracoxib 
group and 17 in the NSAID group) was similar to that which 
occurred in the rofecoxib group in the VIGOR study and the 
study had greater statistical power. Nonetheless, the criticism 
that patients with an increased risk of cardiovascular events 
were excluded may be valid.
The results of the TARGET study argue that the 
differences in cardiovascular outcomes between the CLASS 
and VIGOR studies were principally because of differ-
ences in selectivity for COX-2 inhibition. The results also 
argue against the hypothesis that an imbalance between 
thromboxane and prostacyclin production results in a risk of 
thrombotic and other cardiovascular events and that this is 
a class effect of COX-2 speciﬁ  c inhibitors. However, others 
remain unconvinced that the results of the TARGET study 
provide evidence against the thromboxane/prostacyclin 
imbalance hypothesis, although these commentaries have 
often adopted the premise that the hypothesis is true without 
a discussion of all the epidemiological and mechanistic data 
(Clark et al 2004; Vonkeman et al 2006).
Epidemiological studies
Numerous epidemiological studies have been performed 
comparing the risk of cardiovascular events (almost 
exclusively myocardial infarction) between users of 
COX-2 speciﬁ  c inhibitors, NSAIDS and non-users of anti-
inﬂ  ammatory drugs. These studies have the inherent problem 
that the results may be biased because of differences in the 
populations using different drugs that may affect their risk 
of having a myocardial infarct. Correction for potential bias 
is generally made in the statistical analysis, but it always 
remains possible that unrecognized bias persists.
The studies have varied widely in their scientiﬁ  c quality. 
In general, studies involving large numbers of subjects are 
likely to be more reliable than those with smaller numbers, 
and studies in which the data have been collected prospec-
tively are more reliable than those in which retrospective 
collection of data have been used.
A tabular summary of all of the studies that have com-
pared COX-2 specific inhibitors and/or NSAIDS with 
non-users of these drugs is presented in Table 4.
A positive association between NSAID use and myocar-
dial infarction was ﬁ  rst described by Garcia-Rodriguez in 2000 
(Garcia-Rodriguez et al 2000). The risk of myocardial infarction 
appeared to be greatest in those who had recently commenced 
taking the drugs, an observation that has also been made in a 
number of other studies. Overall, the studies presented in Table 4 
provide evidence that a number of NSAIDS may be associated 
with an increased risk of myocardial infarction, and that the risk 
varies between different drugs. Rofecoxib has been associated 
with an increased risk of myocardial infarction in 12 out of 14 
studies which have evaluated its use. Celecoxib has been associ-
ated with a statistically signiﬁ  cant risk of myocardial infarction 
in four out of 15 studies (Johnsen et al 2005; Singh and Mithal, 
2005; Andersohn et al 2006; Motsko et al 2006). In the ﬁ  rst study 
the increase in risk only occurred in patients who had recently 
commenced taking the drug. There was no signiﬁ  cant difference 
between celecoxib use and remote use of anti-inﬂ  ammatory 
drugs for the primary endpoint, which was long term use of the Therapeutics and Clinical Risk Management 2007:3(5) 839
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Table 4 Summary of population studies that have assessed the relationship between NSAID or selective COX-2 inhibitor therapy 
and cardiovascular events. Studies in which the number of events are not provided for each drug on which the relative risks were 
based have a ? after the name of the drug. Statistically signiﬁ  cant results are highlighted in italics
Author/year  Design  Endpoints  Number of  Relative risks  Comment
     events  (adjusted)  compared
        to non-use unless
       otherwise  stated
Garcia-  Prospective case  First ever fatal or  Current NSAID    Recent initiation of
Rodriguez et al  control study in  non-fatal AMI  use 167  1.45 (1.18–1.79)  NSAID therapy
2000 (July)  women 50–74 years    Duration of therapy    associated with AMI
      <60 days 70  1.76 (1.31–2.38)
     Duration  61–365
      days 40  1.33 (0.91–1.95)
     Duration  >365
      days 57  1.25 (0.90–1.72)
      Low/medium dose 19  1.22 (0.71–2.09)
      High dose 38  1.25 (0.85–1.84)
      Past user 344  0.89 (0.76–1.05)
Schlienger et al  Retrospective case  First ever AMI  All NSAIDS 3319  1.17 (0.99–1.37)  Did not look at
2002 (September)  control in patients      1.20 (0.94–1.55) for  individual NSAIDS
  ≤ 75 years free from      long term use
 cardiovascular  disease
Ray et al  Retrospective  AMI or CHD death  Celecoxib  0.96 (0.76–1.21)
2002 (October)  cohort    (current) 75
     Celecoxib  0.88  (0.67–1.16)
     (new)  55
      Rofecoxib <25 mg  1.03 (0.78–1.35)
      (current) 55  1.02 (0.76–1.37)
     (new)  47
      Rofecoxib >25 mg  1.70 (0.98–2.75)
     (Current)  13  1.93 (1.09–3.43)
     (new)  12
Mamdami et al  Retrospective  AMI  Celecoxib 75  0.9 (0.7–1.2)
2003 (February)  cohort    Rofecoxib 58  1.0 (0.8–1.4)
      Naproxen 15  1.0 (0.6–1.7)
      Other NSAIDS 134  1.2 (0.9–1.4)
Whelton et al  Retrospective cohort  AMI or stroke  Celecoxib ?  1.35 (0.98–1.86)  Event numbers not given
2003 (February)  in hypertensives    Rofecoxib ?  2.45 (1.71–3.51)  Years of exposure 453
  with OA    Other NSAIDS ?  1.11 (0.74–1.67)  to 3612. Contribution of
          stroke not given.
Kimmel et al  Prospective  First, non-fatal  NSAIDS ?  0.53 (0.42–0.67)  Claims NSAIDS are
2004 (March)  case control  AMI  Ibuprofen ?  0.52 (0.39–0.69)  cardioprotective and do
     Naproxen  ?  0.48 (0.28–0.82)  not interfere with the
         beneﬁ  cial effects of aspirin
Kurth et al  Retrospective  First fatal or non-fatal  All NSAIDS <    Very small study. All
2003 (September)  subgroup analysis of  AMI  59 days/yr 26  1.21 (0.78–1.87)  patients on aspirin. No
  randomized trial of    All NSAIDS >    information on individual
  aspirin verses placebo    60 days/yr 6  2.86 (1.25–6.56) NSAIDS
  in US Physicians
Solomon et al  Retrospective,  AMI coded as 1st  Celecoxib 2140  0.93 (0.84–1.02)  *marginal (P = 0.054)
2004 (May)  case-control in adults  or 2nd discharge  Rofecoxib 941  1.14(1.00–1.31)*  Data for other NSAIDS
  over 65 years (mean  diagnosis    Rofecoxib/celecoxib  obtained but not
  age 81 years)      1.24 (1.05–1.46)  compared with non-use
Garcia-  Prospective case  Fatal and non-  All NSAIDS 4975  1.07 (0.95–1.20)  Risk of AMI markedly
Rodriguz et al  control study in  fatal AMI  Naproxen 49  0.89 (0.64–1.24)  increased in patients
2004 (June)  patients aged <70.    Ibuprofen 155  1.06 (0.87–1.29)  prescribed NSAIDS for
                (Continued)Therapeutics and Clinical Risk Management 2007:3(5) 840
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Table 4 (Continued)
Author/year  Design  Endpoints  Number of  Relative risks  Comment
     events  (adjusted)  compared
        to non-use unless
       otherwise  stated
      Diclofenac 213  1.18 (0.99–1.40)  ill-deﬁ  ned chest
      Ketoprofen 16  1.08 (0.59–1.96)  pain. Diclofenac almost
      Meloxicam 25  0.97 (0.60–1.56)  signiﬁ  cant.
     Piroxicam  16 1.25  (0.69–2.25) Unadjusted odds
      Indomethacin 29  0.86 (0.56–1.32)  1.37 (1.17–1.61)
Shaya et al  Prospective  AMI, stroke, sudden  Celecoxib plus  1.12 (0.67–1.85) for AMI  No evidence of
2005 (January)  cohort,  death, haemorrhagic  rofecoxib 66  comparing celecoxib  differences
  Observational  death (APTC)  Other NSAID 60  and rofecoxib  between 
    criteria. Also AMI  (No non-user Group  combined with other  celecoxib or 
    alone.  comparison)  NSAIDS. For APTC,  rofecoxib and 
        celecoxib vs NSAIDS  other NSAIDS
       1.19  (0.93–1.51);
        rofecoxib vs NSAIDS
       0.99  (0.76–1.30)
Graham et al  Prospective,  AMI,SCD (Note that  Celecoxib 126  0.84 (0.67–1.04)  Signiﬁ  cant increase in
2005 (January)  case-control,  non-AMI ACS and  Ibuprofen 670  1.06 (0.96–1.17)  risk of AMI/SCD for
 adults  18–84.  revascularization  Naproxen 367  1.14 (1.00–1.30)  all anti-inﬂ  . (11%) driven
   not included)  Rofecoxib 68  1.34 (0.98–1.82)  driven mostly by the
     Rof ≤25 mg 58  1.23 (0.89–1.71)  effects of NSAIDS
     Rof  ≥25 mg 10  3.00 (1.09–8.31)  (294 vs 1571 events)
      Other NSAID 534  1.13 (1.01–1.27)
     All  anti-inﬂ  am. 1720  1.11 (1.03–1.19)
Kimmel et al  Prospective,  Hospitalization  Celecoxib 18  0.43 (0.23–0.79)  Small study, very
2005 (February)  case control,  for non-fatal AMI  Rofecoxib 27  1.16 (0.70–1.93)  limited endpoint.
  adults 40–75  only  NSAIDS 319  0.61 (0.52–0.71)
Levesque et al  Retrospective,  Hospitalization  Celecoxib 287  0.99 (0.85–1.16)
2005 (April)  case-control  for >3 days for  Rofecoxib 239  1.24 (1.05–1.46)
  adults over 66.  fatal or non-fatal  Naproxen 23  1.17 (0.75–1.84)
  (current use)  AMI  Other NSAID 51  1.00 (0.73–1.37)
Fischer et al  Retrospective  First time AMI  All NSAIDS 650  1.07 (0.96–1.19)
2005 (April)  case control    Ibuprofen ?  1.16 (0.92–1.46)
  current use of    Naproxen ?  0.96 (0.66–1.38)
 NSAIDS    Diclofenac  ?  1.34 (1.00–1.51)
Johnsen et al   Retrospective  Hospitalization for  Celecoxib 71  1.25 (0.97–1.62)  Numbers for naproxen
2005 (May)  case control study  AMI coded as their  Cel. (new) 35  2.13 (1.45–3.13)  small. All NSAIDS
  aged 20 or greater.  1st diagnosis. Data  Rofecoxib 119  1.80 (1.47–2.21)  commenced within
    included new users  Rof. (new) 39  2.52 (1.74–3.64)  previous 30 days
    (1st Rx within last  *Other COX2 57  1.45 (1.09–1.930) associated  with  ↑ risk of 
    30 days.  *Other (new) 22  3.37 (2.05–5.53)  AMI. Long term
      Naproxen 26  1.50 (0.99–2.29)  treatment with
      Napr. (new) 4  1.65 (0.57–4.63)  traditional NSAIDS or
      Other NSAID 532  1.68 (1.52–1.85)  rofecoxib associated with
      Other NSAID (new) 65  2.65 (2.00–3.50)  ↑ AMI
          * included meloxicam
Hippisley-Cox   Retrospective, case  First ever AMI   Remote use    Recent use of ALL
et al 2005 (June)  control study aged   (?including fatal)   Celecoxib 137  1.14 (0.93–1.40)  anti-inﬂ  ammatories
  25–100. Prior AMI     Rofecoxib 219  1.05 (0.89–1.24)  other than celecoxib
  excluded but 28%     Other COX2* 200  0.93 (0.79–1.10)  associated with ↑ risk
  recorded as having     Ibuprofen 1496  1.05 (0.98–1.12)  of AMI. Remote use of
  prior IHD. Cases and     Diclofenac 1311  1.13 (1.05–1.21)  some NSAIDS associated
 controls  classiﬁ  ed as no    Naproxen 332  1.27 (1.01–1.60) with  ↑ risk of AMI. Risk
  prescription in last year,    Other NSAID 560  1.18 (1.06–1.30)  increased with increasing
               (Continued)Therapeutics and Clinical Risk Management 2007:3(5) 841
NSAIDs and cardiovascular disease
Table 4 (Continued)
Author/year  Design  Endpoints  Number of  Relative risks  Comment
     events  (adjusted)  compared
        to non-use unless
       otherwise  stated
  >3 months prior to       prescription numbers.
  index event     Recent use    Risk not affected by
  (remote), and     Celecoxib 93  1.21 (0.96–1.54)  prior diagnosis of CHD
  <3 months prior    Rofecoxib 151  1.32 (1.09–1.61)  use of aspirin
  to index event     Other COX2 101  1.27 (1.00–1.61)
 (recent).    Ibuprofen  460  1.24 (1.11–1.39)
     Diclofenac  542  1.55 (1.39–1.72)  *other COX2
     Naproxen  96  1.27 (1.01–1.60)  presumably
      Other NSAID 181  1.21 (1.02–1.44  mainly meloxiam.
Singh and Mithal  Retrospective case-  AMI (fatal or   15,343 cases. Distribution   Variable increased risk
2005 (June)  control. Current   non-fatal).  between different    of AMI with recent use
  exposure compared    drugs not available.    of most anti-
  to remote exposure.        inﬂ  ammatories.
     Celecoxib  1.09 (1.02–1.15) (all doses)  Dose response
     Meloxicam  1.37 (1.05–1.78)  relationships found for
     Rofecoxib  1.32 (1.22–1.42)  rofecoxib, diclofenac,
     Valdecoxib  0.99  (0.72–1.37)  naproxen and celecoxib
     Indomethacin  1.71 (1.35–2.17)  (RR at doses ≤200 mg/
     Sulindac  1.41(1.01–1.96)  day 1.01 >200 mg/day
     Ibuprofen  1.11(1.01–1.22) =  1.24.
     nabumetone  0.83  (0.60–1.14)
Huang et al   Retrospective,   AMI and stroke   9602 patients who  AMI (verses   Stroke also lower
2006   cohort     received either therapy  meloxicam)   for celecoxib
      for at least 180 days  0.81 (0.70–0.93) 
     celecoxib,    0.78 (0.63–0.96)  Risk of AMI and stroke
      meloxicam     similar for rofecoxib and
     rofecoxib      meloxicam
Andersohn et al  Case control   AMI   3643 cases
April 2006       13918 controls
     rofecoxib    1.33 (1.02–1.63)
     celecoxib    1.56 (1.23–1.98)
     etoricoxib    2.09 (1.10–3.97)
      valdecoxib   4.60 (0.61–34.51)
     diclofenac    1.36 (1.17–1.58)
      ibuprofen   1.00 (0.86–1.25)
      naproxen   1.16 (0.86–1.58)
      other NSAIDs   1.19 (1.02–1.39)
Solomon et al   Cohort study   AMI and   74838 users of NSAIDs    No altered risk for
May 2006     ischaemic stroke   or coxibs, recently    celecoxib, valdecoxib or
      commenced therapy    other NSAIDs
     (new  users).
      Comparison with     Note reduced 
      non-users.     risk for naproxen 
     rofecoxib    1.15 (1.06–1.25)
     naproxen    0.75 (0.62–0.92)
Motsoko et al   Retrospective   Cardiovascular   11930 users of NSAIDs    Risk greater in elderly.
2006   cohort study   events   or coxibs, 142 CV    No difference between
  1999–2001     events. Comparison of    ibuprofen, naproxen and
      events relative to    etodolac. Other NSAIDs
      ibuprofen <180 days or    not studied. Risk for
      >180 days after starting    celecoxib and rofecoxib
     therapy.    increased  progressively
          after 150 days of therapy.
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drug (Johnsen et al 2005). It is of interest that one investigator 
(Garcia-Rodriguez et al 2004) found a markedly increased risk of 
myocardial infarction in patients who had recently commenced 
NSAID therapy because of ill-deﬁ  ned chest pain. It is possible 
that other studies that have found a greater association between 
NSAID use and myocardial infarction following the recent com-
mencement of therapy may have been partly biased by patients 
taking NSAIDS for undiagnosed ischemic chest pain. The second 
study to show an increased risk of myocardial infarction during 
celecoxib use was very large and had the statistical power to 
detect small differences in relative risk. The relative risk associ-
ated with low doses (≤200 mg) of celecoxib was 1.01 which 
increased to 1.24 at higher doses (Singh and Mithal 2005). A third 
study found a signiﬁ  cant increased risk of myocardial infarction 
for celecoxib (relative risk 1.56) and evidence of a greater risk at 
higher doses than at lower doses (Andersohn et al 2006). A recent 
study found an elevated relative risk of myocardial infarction of 
3.64 for celecoxib compared to ibuprofen. (The relative risk for 
rofecoxib compared to ibuprofen in this study was 6.64). The 
increased risk was only apparent during long term administration 
(>180 days). These data may be consistent with an increased risk 
of myocardial infarction at higher doses of celecoxib and during 
prolonged therapy. In all, 10 studies have found no altered risk in 
myocardial infarction for celecoxib, one has found a signiﬁ  cantly 
reduced risk and four have found an increased risk.
Meloxicam, an NSAID which is claimed to be relatively 
COX-2 specific and which is has a different chemical 
structure to both rofecoxib and celecoxib, was reported in 
one study to have no associated increased risk of myocar-
dial infarction (relative risk 0.97) (Garcia-Rodriguez et al 
2004). In another large, statistically powerful study (Singh 
and Mithal 2005) meloxicam was found to be associated 
with a statistically signiﬁ  cant increased risk of myocardial 
infarction (relative risk 1.37), which was higher than that 
observed for rofecoxib (relative risk 1.32). However, the 
relative risk for meloxicam was lower than that reported 
for the non-selective NSAIDs indomethacin (relative risk 
1.71) and sulindac (relative risk 1.41). A population study 
in Taiwan found that the long term use of meloxicam was 
associated with a greater risk of myocardial infarction and 
stroke that celecoxib use. The risk of myocardial infarction 
and stroke amongst rofecoxib users in this study was similar 
to that found for meloxicam use (Huang et al 2006). A pooled 
analysis of randomized, controlled studies of meloxicam 
therapy of up to 60 days duration found that meloxicam was 
associated with a statistically signiﬁ  cantly lower number of 
thromboembolic complications than the NSAID diclofenac 
(0.2% verses 0.8% respectively) but a similar incidence of 
thromboembolic events to naproxen and piroxicam (Singh 
and Lanes 2004). A large study of all myocardial infarctions 
in Finland from 2000 to 2003 found a signiﬁ  cantly increased 
realtive risk for meloxicam of 1.24.
It should be noted that population studies have not yet been 
able adequately to assess the cardiovascular risk associated 
Table 4 (Continued)
Author/year  Design  Endpoints  Number of  Relative risks  Comment
     events  (adjusted)  compared
        to non-use unless
       otherwise  stated
     >180  days
      celecoxib (18)   3.64 (1.36–9.70)
      rofecoxib (8)   6.64 (2.17–20.8)
     <180  days
      celecoxib (21)  0.75 (0.42–1.35)
     rofecoxib  (9)  0.85  (0.39–1.86)
Helin-Salmivaara  Nationwide   First-time AMI   33039 cases,     Most NSAIDs had
et al 2006 June  (Finland ) case-    138949 controls    relative risk of of ∼ 1.40,
  control study     Any NSAID   1.40 (1.33–1.48)   including  ibuprofen.
 2000–2003    Conventional  NSAID  1.34 (1.26–1.43)   (Naproxen risk
      Semi selective   1.50 (1.32–1.71)   1.19 (1.02–1.38). 
      (etodolac,   1.35 (0.44–4.17)   No evidence of 
     nimensuide,    1.69 (1.43–1.99)   increasing risk with
      meloxicam)   1.24 (0.99–1.55)   longer duration of
     Coxibs    1.31 (1.13–1.50)  therapy.  No 
      (celecoxib,   1.06 (0.83–1.34)   increased risk for 
     rofecoxib,    1.44 (1.20–1.72)   celecoxib.
  etoricoxib)   2.21 (1.18–4.14)Therapeutics and Clinical Risk Management 2007:3(5) 843
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(Fitzgerald 2003) while leaving thromboxane formation 
unchanged, it is likely that other mechanisms such as the 
nitric oxide and endothelium derived hyperpolarization factor 
(EDHF) pathways compensate to an extent for this effect. 
Nonetheless, these potential compensatory mechanisms 
could theoretically fail in patients with vascular disease or 
cardiovascular risk factors, placing them at greatest risk for 
cardiovascular complications of selective COX-2 inhibitor 
therapy. However, measurements of endothelium dependent 
vasodilator responses (an independent predictor of future 
cardiovascular events) have been shown to remain unchanged 
in patients with ischemic heart disease receiving long term 
rofecoxib therapy (Bogarty et al 2004) and to improve in 
a similar group of patients receiving celecoxib therapy 
(Chenevard et al 2003). While COX-2 inhibition has been 
reported to reduce the late phase of myocardial ischemic 
preconditioning and increase infarct size in animal models, 
this effect occurs with both selective and non-selective COX 
inhibitors (Shinamura et al 2002).
Other potential mechanisms exist via which selective 
and non-selective COX inhibitors may increase the risk 
of myocardial infarction and other serious cardiovascular 
events. Rofecoxib has been described to have pro-oxidant 
activity and to increase the formation of reactive molecules 
leading to increased oxidative damage to LDL-cholesterol 
(Walter et al 2004). Selective and non-selective COX inhibi-
tors may increase blood pressure leading to a short-term and 
long-term increase in cardiovascular events (Aw et al 2005). 
In particular, rofecoxib has been demonstrated to have a 
greater effect on blood pressure than celecoxib and some 
other non-selective NSAIDs (Sowers et al 2005).
The individual effect that a NSAID or COX-2 inhibitor 
has in modifying the risk of cardiovascular events may 
depend upon a complex interaction of pharmacological 
properties including duration and extent of platelet inhibition, 
extent of blood pressure rise and properties that appear to be 
unique to the molecule. Examples of the latter include the 
pro-oxidant effects of rofecoxib and the ability of celecoxib 
to improve endothelial function.
Conclusion
The published scientiﬁ  c literature suggests that both speciﬁ  c 
and non-speciﬁ  c COX inhibitors may increase the risk of 
myocardial infarction and other serious cardiovascular 
events, but that the effect varies between the individual drugs. 
There is little evidence to support the proposition that an 
imbalance of thromboxane and prostacyclin resulting from 
COX-2 speciﬁ  c inhibition increases the risk of cardiovascular 
with the newer selective COX-2 inhibitors, lumiracoxib, 
etoricoxib and valdecoxib. Data for valdecoxib have been 
included in two studies and was not found to be associated 
with an increased risk of myocardial infarction (Singh and 
Mithal 2005; Andersohn et al 2006). Etoricoxib has been 
evaluated in two studies and found to be associated with a 
signiﬁ  cantly increased relative risk of myocardial infarction 
of 2.02 in one (Andersohn et al 2006) and 2.21 in the other 
(Helin-Salmivaara et al 2006).
A large, recent Finnish study of over 33,000 myocardial in-
farctions found an increased relative risk of 1.34 for all conven-
tional NSAIDs combined and 1.31 for all coxibs combined. The 
relative risk values for individual NSAIDs were similar over 
a wide range of drugs, the lowest values being for ketoprofen 
(1.11) and naproxen (1.19) (Helin-Salmivaara et al 2006). 
Etoricoxib had the highest value amongst the selective COX-2 
inhibitors (2.21) while the relative risk for rofecoxib was 1.6. 
Of the three selective COX-2 inhibitors studied, only celecoxib 
therapy was not associated with a signiﬁ  cantly increased risk 
of myocardial infarction (relative risk 1.06).
The interpretation of population studies is hampered by 
the fact that they are not randomized and are often retrospec-
tive, and there is a signiﬁ  cant potential for unrecognized 
selection bias. In addition, comparisons between studies 
that assess different endpoints in different populations are 
difﬁ  cult. Nonetheless, the population studies as a group sug-
gest that COX inhibitors as a class (whether COX-2 selec-
tive or not) have the potential to increase the risk of serious 
cardiovascular events. While there appear to be differences 
between individual drugs in the risk of producing serious 
cardiovascular events, this does not appear to be clearly 
related to the degree of COX-2 selectivity. Rofecoxib has 
been shown to be associated with increased cardiovascular 
events fairly consistently, but some commonly used tradi-
tional NSAIDs (indomethicin, diclofenac, sulindac) have 
been reported in some studies to have a higher risk than 
rofecoxib (Hippisley-Cox et al 2005; Singh and Mithal 2005). 
Celecoxib has not been associated with an increased risk of 
serious cardiovascular events in most of the studies which 
have evaluated its risk.
Mechanisms via which non-selective 
or selective COX-2 inhibitors may 
increase the risk of cardiovascular 
events
While there is evidence that both rofecoxib and celecoxib 
reduce prostacyclin formation in normal volunteers Therapeutics and Clinical Risk Management 2007:3(5) 844
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events and that this is a class effect. The evidence available 
so far (which must be accepted as being indirect and 
incomplete) suggests that a higher cardiovascular risk may 
be associated with rofecoxib, while a lower cardiovascular 
risk may be associated with celecoxib. Some NSAIDs, 
particularly indomethacin, diclofenac and meloxicam may 
have cardiovascular risks similar to rofecoxib. There is a 
much greater body of evidence supporting the relative car-
diovascular safety of celecoxib when used at the usual doses 
to treat arthritis than for any of the other selective COX-2 
inhibitors or NSAIDs.
It will be important to establish the individual cardio-
vascular safety of novel COX inhibitors before they are 
introduced into widespread use. It is important at the pres-
ent time that some widely used NSAIDs may have a similar 
cardiovascular risk to rofecoxib, which was removed from 
the market because of cardiovascular toxicity.
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